Abstract
Purpose
The combination of cisplatin and gemcitabine-based chemotherapy has been recommended as a preferred regimen for pancreatic ductal adenocarcinoma (PDAC) patients with germline-based mutations. However, the underlying mechanism remains poorly elucidated. Therefore, our study aimed to explore the mechanistic basis of the cell-killing activity of gemcitabine plus cisplatin and identify potential therapeutic targets.
Methods
First, we explored the synergistic cytotoxic effects of gemcitabine and cisplatin on PDAC through in vitro and in vivo experiments. Then, we investigated ferroptosis-related biomarkers, to assess the impact of the combination therapy on ferroptosis. Using bioinformatics methods, we identified SAT1 as a potential key mediator of ferroptosis induced by gemcitabine and cisplatin. We tested the polyamine levels in PDAC cells by LC–MS after overexpressed or knocked down SAT1, and explored the role of polyamines in ferroptosis using exogenous supplementation. Finally, we explored the regulatory effect of Sp1 on SAT1 through ChIP-qPCR and dual-luciferase reporter assay.
Results
Gemcitabine plus cisplatin enhanced cell death and induced ferroptosis in PDAC. This combination upregulated SAT1 transcription by inhibiting Sp1. SAT1 activation promoted the catabolism of spermine and spermidine, leading to iron accumulation and lipid peroxide generation, ultimately resulting in ferroptosis.
Conclusions
In summary, our findings suggested the gemcitabine and cisplatin combination therapy induced ferroptosis in a GSH-independent manner in PDAC. The combined treatment inhibited Sp1 and upregulated SAT1 transcription, leading to the breakdown of spermine and spermidine. Therefore, targeting SAT1-induced polyamine metabolism may represent a promising therapeutic strategy for PDAC.
Similar content being viewed by others
Data availability
The original contributions presented in the study are included in the article/Supplementary Material, and the RNA sequencing data were accessed from GEO database (https://www.ncbi.nlm.nih.gov/geo/), further inquiries can be directed to the corresponding authors.
References
R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, CA A Cancer J Clin 71, 7 (2021)
W. Park, A. Chawla, E.M. O’Reilly, JAMA 326, 851 (2021)
J. Yang, R. Xu, C. Wang, J. Qiu, B. Ren, L. You, Cancer Commun (Lond) 41, 1257 (2021)
C. Springfeld, D. Jäger, M.W. Büchler, O. Strobel, T. Hackert, D.H. Palmer, J.P. Neoptolemos, Presse Med 48, e159 (2019)
B. J. Raphael, R. H. Hruban, A. J. Aguirre, R. A. Moffitt, J. J. Yeh, C. Stewart, A. G. Robertson, A. D. Cherniack, M. Gupta, G. Getz, S. B. Gabriel, M. Meyerson, C. Cibulskis, S. S. Fei, T. Hinoue, H. Shen, P. W. Laird, S. Ling, Y. Lu, G. B. Mills, R. Akbani, P. Loher, E. R. Londin, I. Rigoutsos, A. G. Telonis, E. A. Gibb, A. Goldenberg, A. M. Mezlini, K. A. Hoadley, E. Collisson, E. Lander, B. A. Murray, J. Hess, M. Rosenberg, L. Bergelson, H. Zhang, J. Cho, G. Tiao, J. Kim, D. Livitz, I. Leshchiner, B. Reardon, E. Van Allen, A. Kamburov, R. Beroukhim, G. Saksena, S. E. Schumacher, M. S. Noble, D. I. Heiman, N. Gehlenborg, J. Kim, M. S. Lawrence, V. Adsay, G. Petersen, D. Klimstra, N. Bardeesy, M. D. M. Leiserson, R. Bowlby, K. Kasaian, I. Birol, K. L. Mungall, S. Sadeghi, J. N. Weinstein, P. T. Spellman, Y. Liu, L. T. Amundadottir, J. Tepper, A. D. Singhi, R. Dhir, D. Paul, T. Smyrk, L. Zhang, P. Kim, J. Bowen, J. Frick, J. M. Gastier-Foster, M. Gerken, K. Lau, K. M. Leraas, T. M. Lichtenberg, N. C. Ramirez, J. Renkel, M. Sherman, L. Wise, P. Yena, E. Zmuda, J. Shih, A. Ally, M. Balasundaram, R. Carlsen, A. Chu, E. Chuah, A. Clarke, N. Dhalla, R. A. Holt, S. J. M. Jones, D. Lee, Y. Ma, M. A. Marra, M. Mayo, R. A. Moore, A. J. Mungall, J. E. Schein, P. Sipahimalani, A. Tam, N. Thiessen, K. Tse, T. Wong, D. Brooks, J. T. Auman, S. Balu, T. Bodenheimer, D. N. Hayes, A. P. Hoyle, S. R. Jefferys, C. D. Jones, S. Meng, P. A. Mieczkowski, L. E. Mose, C. M. Perou, A. H. Perou, J. Roach, Y. Shi, J. V. Simons, T. Skelly, M. G. Soloway, D. Tan, U. Veluvolu, J. S. Parker, M. D. Wilkerson, A. Korkut, Y. Senbabaoglu, P. Burch, R. McWilliams, K. Chaffee, A. Oberg, W. Zhang, M.-C. Gingras, D. A. Wheeler, L. Xi, M. Albert, J. Bartlett, H. Sekhon, Y. Stephen, Z. Howard, M. Judy, A. Breggia, R. T. Shroff, S. Chudamani, J. Liu, L. Lolla, R. Naresh, T. Pihl, Q. Sun, Y. Wan, Y. Wu, S. Jennifer, K. Roggin, K.-F. Becker, M. Behera, J. Bennett, L. Boice, E. Burks, C. G. Carlotti Junior, J. Chabot, D. Pretti da Cunha Tirapelli, J. Sebastião dos Santos, M. Dubina, J. Eschbacher, M. Huang, L. Huelsenbeck-Dill, R. Jenkins, A. Karpov, R. Kemp, V. Lyadov, S. Maithel, G. Manikhas, E. Montgomery, H. Noushmehr, A. Osunkoya, T. Owonikoko, O. Paklina, O. Potapova, S. Ramalingam, W. K. Rathmell, K. Rieger-Christ, C. Saller, G. Setdikova, A. Shabunin, G. Sica, T. Su, T. Sullivan, P. Swanson, K. Tarvin, M. Tavobilov, L. B. Thorne, S. Urbanski, O. Voronina, T. Wang, D. Crain, E. Curley, J. Gardner, D. Mallery, S. Morris, J. Paulauskis, R. Penny, C. Shelton, T. Shelton, K.-P. Janssen, O. Bathe, N. Bahary, J. Slotta-Huspenina, A. Johns, H. Hibshoosh, R. F. Hwang, A. Sepulveda, A. Radenbaugh, S. B. Baylin, M. Berrios, M. S. Bootwalla, A. Holbrook, P. H. Lai, D. T. Maglinte, S. Mahurkar, T. J. Triche, D. J. Van Den Berg, D. J. Weisenberger, L. Chin, R. Kucherlapati, M. Kucherlapati, A. Pantazi, P. Park, G. Saksena, D. Voet, P. Lin, S. Frazer, T. Defreitas, S. Meier, L. Chin, S. Y. Kwon, Y. H. Kim, S.-J. Park, S.-S. Han, S. H. Kim, H. Kim, E. Furth, M. Tempero, C. Sander, A. Biankin, D. Chang, P. Bailey, A. Gill, J. Kench, S. Grimmond, A. Johns, A. P. Cancer Genome Initiative (APGI, R. Postier, R. Zuna, H. Sicotte, J. A. Demchok, M. L. Ferguson, C. M. Hutter, K. R. Mills Shaw, M. Sheth, H. J. Sofia, R. Tarnuzzer, Z. Wang, L. Yang, J. (Julia) Zhang, I. Felau, and J. C. Zenklusen, Cancer Cell 32, 185 (2017).
E.A. Collisson, P. Bailey, D.K. Chang, A.V. Biankin, Nat Rev Gastroenterol Hepatol 16, 207 (2019)
G.S. Jameson, E. Borazanci, H.M. Babiker, E. Poplin, A.A. Niewiarowska, M.S. Gordon, M.T. Barrett, A. Rosenthal, A. Stoll-D’Astice, J. Crowley, L. Shemanski, R.L. Korn, K. Ansaldo, L. Lebron, R.K. Ramanathan, D.D. Von Hoff, JAMA Oncol 6, 125 (2020)
M. Reni, S. Zanon, G. Balzano, P. Passoni, C. Pircher, M. Chiaravalli, C. Fugazza, D. Ceraulo, R. Nicoletti, P.G. Arcidiacono, M. Macchini, U. Peretti, R. Castoldi, C. Doglioni, M. Falconi, S. Partelli, L. Gianni, Eur J Cancer 102, 95 (2018)
H. Okada, T.W. Mak, Nat Rev Cancer 4, 592 (2004)
C. Holohan, S. Van Schaeybroeck, D.B. Longley, P.G. Johnston, Nat Rev Cancer 13, 714 (2013)
S.J. Dixon, K.M. Lemberg, M.R. Lamprecht, R. Skouta, E.M. Zaitsev, C.E. Gleason, D.N. Patel, A.J. Bauer, A.M. Cantley, W.S. Yang, B. Morrison, B.R. Stockwell, Cell 149, 1060 (2012)
Q. Liu, K. Wang, Cell Biol Int 43, 1245 (2019)
L. Zhou, C. Yang, W. Zhong, Q. Wang, D. Zhang, J. Zhang, S. Xie, M. Xu, Biochem Pharmacol 193, 114813 (2021)
X. Zhang, S. Sui, L. Wang, H. Li, L. Zhang, S. Xu, X. Zheng, J Cell Physiol 235, 3425 (2020)
E.W. Gerner, F.L. Meyskens, Nat Rev Cancer 4, 781 (2004)
Y. Terui, T. Yoshida, A. Sakamoto, D. Saito, T. Oshima, M. Kawazoe, S. Yokoyama, K. Igarashi, K. Kashiwagi, Int J Biochem Cell Biol 99, 147 (2018)
K. Soda, Cells 11, 164 (2022)
D.-H. Bae, D.J.R. Lane, P.J. Jansson, D.R. Richardson, Biochim Biophys Acta Gen Subj 1862, 2053 (2018)
A.E. Pegg, Am J Physiol Endocrinol Metab 294, E995 (2008)
Y. Ou, S.-J. Wang, D. Li, B. Chu, W. Gu, Proc Natl Acad Sci USA 113, E6806 (2016)
W. Wei, Q. Hu, W. Li, M. Li, S. Dong, Y. Peng, J. Yin, Y. Lu, L. Liu, and Q. Zhao, DNA and Cell Biology 41, 116 (2021)
J. Guo, B. Xu, Q. Han, H. Zhou, Y. Xia, C. Gong, X. Dai, Z. Li, G. Wu, Cancer Res Treat 50, 445 (2018)
J.-L. Roh, E.H. Kim, H. Jang, D. Shin, Redox Biol 11, 254 (2017)
H. Zhang, T. Deng, R. Liu, T. Ning, H. Yang, D. Liu, Q. Zhang, D. Lin, S. Ge, M. Bai, X. Wang, L. Zhang, H. Li, Y. Yang, Z. Ji, H. Wang, G. Ying, Y. Ba, Mol Cancer 19, 43 (2020)
Z. Ye, Q. Zhuo, Q. Hu, X. Xu, Mengqi liu, Z. Zhang, W. Xu, W. Liu, G. Fan, Y. Qin, X. Yu, S. Ji, Redox Biol 38, 101807 (2021)
S. Zhu, Q. Zhang, X. Sun, H.J. Zeh, M.T. Lotze, R. Kang, D. Tang, Cancer Res 77, 2064 (2017)
J. Du, X. Wang, Y. Li, X. Ren, Y. Zhou, W. Hu, C. Zhou, Q. Jing, C. Yang, L. Wang, H. Li, L. Fang, Y. Zhou, X. Tong, Y. Wang, Cell Death Dis 12, 705 (2021)
I.N. Sari, Y.-G. Yang, Y.T. Wijaya, N. Jun, S. Lee, K.S. Kim, J. Bajaj, V.G. Oehler, S.-H. Kim, S.-Y. Choi, S.-H. Park, D.-W. Kim, T. Reya, J. Han, H.Y. Kwon, Oncogene 40, 603 (2021)
B.-K. Yin, Z.-Q. Wang, IJMS 22, 12445 (2021)
A. Banerjee, B. Mahata, A. Dhir, T.K. Mandal, K. Biswas, J Biol Chem 294, 1005 (2019)
T. Okusaka, J. Furuse, J Gastroenterol 55, 369 (2020)
J. Lee, J.H. You, D. Shin, J.-L. Roh, Theranostics 10, 7775 (2020)
Q. Meng, S. Shi, C. Liang, D. Liang, J. Hua, B. Zhang, J. Xu, X. Yu, Oncogene 37, 5843 (2018)
G. Marverti, S. Bettuzzi, S. Astancolle, C. Pinna, M.G. Monti, M.S. Moruzzi, Eur J Cancer 37, 281 (2001)
G. Marverti, M.G. Monti, A.E. Pegg, D.E. McCloskey, S. Bettuzzi, A. Ligabue, A. Caporali, D. D’Arca, M.S. Moruzzi, Carcinogenesis 26, 1677 (2005)
J. Wang, S. Li, J. Wang, F. Wu, Y. Chen, H. Zhang, Y. Guo, Y. Lin, L. Li, X. Yu, T. Liu, Y. Zhao, Aging (Albany NY) 12, 650 (2020)
B. Tadolini, Biochem J 249, 33 (1988)
D.J.R. Lane, D.-H. Bae, A.R. Siafakas, Y. Suryo Rahmanto, L. Alkra, P.J. Jansson, R.A. Casero, D.R. Richardson, Biochim Biophys Acta Mol Basis Dis 1864, 2793 (2018)
F. Gaboriau, A. Kreder, N. Clavreul, J.-P. Moulinoux, J.-G. Delcros, G. Lescoat, Biochem Pharmacol 67, 1629 (2004)
B.R. Stockwell, J.P. Friedmann Angeli, H. Bayir, A.I. Bush, M. Conrad, S.J. Dixon, S. Fulda, S. Gascón, S.K. Hatzios, V.E. Kagan, K. Noel, X. Jiang, A. Linkermann, M.E. Murphy, M. Overholtzer, A. Oyagi, G.C. Pagnussat, J. Park, Q. Ran, C.S. Rosenfeld, K. Salnikow, D. Tang, F.M. Torti, S.V. Torti, S. Toyokuni, K.A. Woerpel, D.D. Zhang, Cell 171, 273 (2017)
S. Doll, F.P. Freitas, R. Shah, M. Aldrovandi, M.C. da Silva, I. Ingold, A. Goya Grocin, T.N. Xavier da Silva, E. Panzilius, C.H. Scheel, A. Mourão, K. Buday, M. Sato, J. Wanninger, T. Vignane, V. Mohana, M. Rehberg, A. Flatley, A. Schepers, A. Kurz, D. White, M. Sauer, M. Sattler, E.W. Tate, W. Schmitz, A. Schulze, V. O’Donnell, B. Proneth, G.M. Popowicz, D.A. Pratt, J.P.F. Angeli, M. Conrad, Nature 575, 693 (2019)
K. Bersuker, J.M. Hendricks, Z. Li, L. Magtanong, B. Ford, P.H. Tang, M.A. Roberts, B. Tong, T.J. Maimone, R. Zoncu, M.C. Bassik, D.K. Nomura, S.J. Dixon, J.A. Olzmann, Nature 575, 688 (2019)
V.A.N. Kraft, C.T. Bezjian, S. Pfeiffer, L. Ringelstetter, C. Müller, F. Zandkarimi, J. Merl-Pham, X. Bao, N. Anastasov, J. Kössl, S. Brandner, J.D. Daniels, P. Schmitt-Kopplin, S.M. Hauck, B.R. Stockwell, K. Hadian, J.A. Schick, ACS Cent Sci 6, 41 (2020)
M. Soula, R. A. Weber, O. Zilka, H. Alwaseem, K. La, F. Yen, H. Molina, J. Garcia-Bermudez, D. A. Pratt, and K. Birsoy, Nat Chem Biol 16, 1351 (2020)
J. Zhao, Y. Wu, S. Liang, X. Piao, Neuroscience 485, 78 (2022)
A. Muth, M. Madan, J.J. Archer, N. Ocampo, L. Rodriguez, O. Phanstiel, J Med Chem 57, 348 (2014)
K. Soda, IJMS 19, 3106 (2018)
C. Liu, D. Xu, J. Sjöberg, P. Forsell, M. Björkholm, H.-E. Claesson, Exp Cell Res 297, 61 (2004)
Funding
This research was funded by the National Natural Science Foundation of China (Grant No. 81870390), Scientific Research Project of Wuhan Science and Technology Bureau (No: 2019020701011476), and Hubei Provincial Natural Science and Technology Fund (No:2023AFB458).
Author information
Authors and Affiliations
Contributions
Conceptualization, WW, QH, QZ, and LL; methodology, WW, YL, and QH; software, JY, and QH; validation, WW, WY, and YL; formal analysis, YL; investigation, JY; data curation, WW, and YL; writing—original draft preparation, WW; writing—review and editing, WW and LL; visualization, WW; supervision, HZ, QZ, and LL. All authors have read and agreed to the published version of the manuscript.
Corresponding authors
Ethics declarations
Ethics statement
The animal study (ZN2021191) was reviewed and approved by the Zhongnan Hospital of Wuhan University Institutional Animal Care Animal Welfare Committee.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
13402_2023_870_MOESM1_ESM.tif
Supplementary file1 S-Fig 1. Establishment of the stable PANC-1 cell line with knockdown of SAT1. A. Transfection efficiency of shSAT1 lentiviral vector was observed by fluorescence microscope in PANC-1cells. B. Western blot assay for SAT1 in the stable PANC-1 cell line with knockdown of SAT1 in the presence or absence combination treatment of gemcitabine and cisplatin. (TIF 40751 KB)
13402_2023_870_MOESM2_ESM.tif
Supplementary file2 S-Fig 2. Repetitive Western blot bands and grayscale analysis in PDAC cells treated with mono or combination of gemcitabine and cisplatin. (TIF 32396 KB)
13402_2023_870_MOESM4_ESM.tif
Supplementary file4 S-Fig 4. Repetitive Western blot bands and grayscale analysis in PDAC cells transfected with SAT1 overexpression plasmid. (TIF 29400 KB)
13402_2023_870_MOESM5_ESM.tif
Supplementary file5 S-Fig5. Repetitive Western blot bands and grayscale analysis in PDAC cells transinfected with SAT1 shRNA. (TIF 31632 KB)
13402_2023_870_MOESM6_ESM.tif
Supplementary file6 S-Fig6. Repetitive Western blot bands and grayscale analysis in PDAC cells supplemented with spermidine or spermine. (TIF 31290 KB)
13402_2023_870_MOESM7_ESM.tif
Supplementary file7 S-Fig7. Repetitive Western blot bands and grayscale analysis in PDAC cells transfected with siSp1. (TIF 27157 KB)
13402_2023_870_MOESM8_ESM.tif
Supplementary file8 S-Fig 8. Sp1 did not bind to the predicted binding site 1 of SAT1 promoter in PDAC. A-B. ASPC-1 and PANC-1 cells were collected for ChIP-PCR (A.) and ChIP-qPCR (B.) with anti-Sp1 antibody and specific primers for binding site 1. IgG was used as negative control. (TIF 26823 KB)
13402_2023_870_MOESM9_ESM.tif
Supplementary file9 S-Fig 9. Sp1 inhibited SAT1 not via the Sp1-HDAC1 complex in PDAC. A. Binding affinity between Sp1 and HDAC1 in PDAC cells, as detected with Co-IP assay (TIF 28621 KB)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Wei, W., Lu, Y., Hu, Q. et al. Synergistic antitumor efficacy of gemcitabine and cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via Sp1-SAT1-polyamine metabolism pathway. Cell Oncol. 47, 321–341 (2024). https://doi.org/10.1007/s13402-023-00870-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13402-023-00870-1